| 张若丹,柯英,曹美,吴雨虹.孟鲁司特钠联合布地奈德福莫特罗对COPD患者肺功能及炎症介质、BNP、ApoA1的影响.[J].中南医学科学杂志.,2023,(4):554-557. |
| 孟鲁司特钠联合布地奈德福莫特罗对COPD患者肺功能及炎症介质、BNP、ApoA1的影响 |
| Effects of montelukast combined with budesonide on pulmonary function, inflammatory mediators, BNP, and ApoA1 in patients with COPD |
| 投稿时间：2023-02-06 修订日期：2023-05-16 |
| DOI：10.15972/j.cnki.43-1509/r.2023.04.019 |
| 中文关键词: 孟鲁司特钠 布地奈德福莫特罗 COPD 肺功能 炎质介质 BNP ApoA1 [ |
| 英文关键词:montelukast budesonide COPD pulmonary function inflammatory mediators BNP ApoA1 |
| 基金项目:四川省医学会伤口疾病(泰阁)专项科研课题(2021TG34) |
|
| 摘要点击次数: 121 |
| 全文下载次数: 100 |
| 中文摘要: |
| 目的探讨孟鲁司特钠联合布地奈德福莫特罗治疗对慢性阻塞性肺疾病(COPD)患者肺功能及炎症介质、脑钠肽(BNP)、载脂蛋白A1(ApoA1)的影响。 方法纳入240例COPD患者,随机分为观察组和对照组各120例。对照组给与布地奈德福莫特罗粉吸入剂治疗,观察组在对照组基础上给与孟鲁司特钠治疗。比较两组临床疗效、炎症因子、BNP、ApoA1和不良反应发生情况。 结果观察组治疗有效率高于对照组(P＜0.05)。观察组咳嗽、咳痰、喘息及呼吸困难改善时间均短于对照组(P＜0.05)。治疗后,两组患者的第1秒用力呼气容积(FEV1)、用力肺活量(FVC)及FEV1/FVC均上升,且观察组均高于对照组(P＜0.05)；两组患者血清白细胞介素-6、肿瘤坏死因子-α、呼出气一氧化碳及嗜酸性粒细胞计数均显著降低,且观察组低于对照组(P＜0.05)；两组患者ApoA1水平均上升,BNP水平均下降,且观察组ApoA1较对照组升高,BNP较对照组降低(P＜0.05)；两组患者疾病影响力、呼吸症状及活动受阻评分均明显降低,且观察组较对照组降低(P＜0.05)。观察组不良反应发生率较对照组降低(P＜0.05)。 结论孟鲁司特钠联合布地奈德福莫特罗治疗COPD临床疗效确切,可有效改善患者的肺功能,降低炎症介质水平和血清BNP水平,调节血清ApoA1水平,提高患者的生活质量,且不良反应较少。 |
| 英文摘要: |
| AimTo explore the effects of montelukast combined with budesonide on lung function, inflammatory mediators, serum brain natriuretic peptide (BNP), and serum apolipoprotein (ApoA1) in patients with chronic obstructive pulmonary disease (COPD). Methods240 COPD patients were included and randomly divided into an observation group and a control group, with 120 cases for each group. The control group was treated with budesonide, and the observation group was treated with montelukast. The clinical efficacy, inflammatory factors, BNP, ApoA1, and incidence of adverse reactions between the two groups were compared. ResultsThe effective rate of treatment group was significantly higher than control group (P＜0.05). The improvement time of cough, expectoration, wheeze and dyspnea in the research group was significantly shorter than that in the control group (P＜0.05). After treatment, the FEV1, FVC and FEV1/FVC values of the two groups were significantly increased, and these values were higher in research group compared the control group (P＜0.05). Serum IL-6, TNF-α, FeNO and EOS counts of patients in the two groups were significantly reduced, and the research group was better than control group (P＜0.05). Serum ApoA1 levels of patients in the two groups were significantly increased, and BNP levels were significantly decreased. Serum ApoA1 level in the research group was higher than that in the control group, and BNP level was lower than that in the control group (P＜0.05). The disease influence, respiratory symptoms and activity disturbance scores of the two groups were significantly reduced, and the score in the research group was significantly lower than that in the control group (P＜0.05). The incidence of adverse reactions in the research group was significantly lower than control group (P＜0.05). ConclusionMontelukast sodium combined with budesonide has reliable clinical effect on patients with COPD. It can effectively improve lung function of patients, reduce levels of inflammatory mediators and serum BNP level, regulate serum ApoA1 level, and improve the quality of life of patients with less adverse reactions. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|